catalog number :
MBS592395
products full name :
mAb anti-human amyloid beta peptide N-terminus
products short name :
[amyloid beta peptide N-terminal]
products name syn :
[Beta amyloid peptide N-terminal; Mouse monoclonal antibody against N-terminal sequence of human amyloid beta peptides]
specificity :
This antibody recognizes the N-terminal peptide (DAEFRHDS) of human beta amyloid peptides and also reacts with full length Abeta40, Abeta42 and Abeta43. Beta amyloid peptide N-terminal
purity :
Protein G affinity purified
form :
Lyophilized from a solution in 0.01M PBS pH7.2
storage stability :
Store at -20 degree C
tested application :
Western Blot (WB), ELISA (EIA)
app notes :
Sandwich ELISA:. This antibody (clone NT 5B8) reacts with full length Abeta40, Abeta42 and Abeta43 at the N-terminus. The antibody can be used as capture antibody in combination with anti- Abeta42 clone CA9 10C11 (Cat. No.: MBS592143) in sandwich ELISA application for the detection of Abeta42. In addition, this antibody can be used as capture antibody for detection of Abeta40 in combination with anti Abeta40 clone CV9 7B10 (Cat. No.:MBS592396)
image1 heading :
Western Blot
other info1 :
Product Type: Primary antibody-Capture antibody in matched antibody pair. Target Protein: Human beta amyloid peptide 42. Immunogen: Full length human beta amyloid peptide 42. Myeloma: Sp2/0-Ag14. Light Chain: Kappa. Reconstitution: Double distilled water is recommended to adjust the final concentration to 1.00 mg/mL.
other info2 :
Research Area: Aging and neurodegenerative diseases
products categories :
Primary antibody; Monoclonal Antibodies to Neurological Disorder Proteins
products description :
Description: Mouse monoclonal antibody against N-terminal sequence of human amyloid beta peptides. Background: Amyloid beta peptides Abeta42 and Abeta40 have been investigated extensively for predicating Alzheimer's disease. A recent study on A Abeta43 in brain showed that Abeta43 is more fibrillogenic than the other amyloid beta peptides and may be useful as a biomarker or therapeutic target for Alzheimer's disease. Since Abeta40, Abeta42 and Abeta43 are different only at the few C-end amino acids, antibody to N-terminal sequence can bind with all three amyloid beta peptides.